Stocks Health care COAG

NASDAQ · Health care

Hemab Therapeutics Holdings, Inc. (COAG)

At June 30, 2026 it held $237.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.

What Hemab Therapeutics Holdings, Inc. does

Hemab Therapeutics Holdings, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker COAG.

Latest SEC filings

What Hemab Therapeutics Holdings, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. September 24, 2026
   Executive or director change 8-K
2. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
3. August 14, 2026
   Passive stake (5% or more) SCHEDULE 13G
4. August 12, 2026
   Passive stake (5% or more) SCHEDULE 13G
5. August 11, 2026
   Quarterly report 10-Q · period to June 30, 2026
6. August 11, 2026
   Quarterly results 8-K
7. August 7, 2026
   Passive stake (5% or more) SCHEDULE 13G
8. August 6, 2026
   Passive stake (5% or more) SCHEDULE 13G
9. August 5, 2026
   Passive stake (5% or more) SCHEDULE 13G
10. May 21, 2026
    Quarterly report 10-Q · period to March 31, 2026

Recent insider filings (Forms 3, 4 and 144): 10, the latest on September 25, 2026. Insider transactions on SEC

Insider trades

What the people running Hemab Therapeutics Holdings, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about COAG

What does Hemab Therapeutics Holdings, Inc. do?

Hemab Therapeutics Holdings, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker COAG.

When did Hemab Therapeutics Holdings, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from September 25, 2026.

Similar companies

Compare COAG with

Compare COAG with any company

Follow COAG

Get an email when Hemab Therapeutics Holdings, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow COAG: get an email when it files

Where the numbers come from

Financial figures are the values Hemab Therapeutics Holdings, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.